Latest news
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma - CancerNetworkCancerNetwork · Thu, 06 Aug 2026 20:19:04 GMTChaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad - BioSpaceBioSpace · Wed, 05 Aug 2026 13:39:37 GMTCapricor’s Duchenne AdCom Didn’t Fail on Science. It Failed on Statistics. - The Clinical Trial VanguardThe Clinical Trial Vanguard · Tue, 04 Aug 2026 07:38:27 GMTDr Vincent Ma: CTGTAC's 10-3 Vote on RP1/Nivo Is “Encouraging” - Targeted OncologyTargeted Oncology · Mon, 03 Aug 2026 19:37:20 GMTReplimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote - BenzingaBenzinga · Fri, 31 Jul 2026 14:09:17 GMTFDA CTGTAC Committee Votes in Favor of Replimune’s RP1 Efficiency Results in Ignyte Study - Pharmaceutical ExecutivePharmaceutical Executive · Fri, 31 Jul 2026 07:00:00 GMTReplimune advisory panel finds IGNYTE efficacy results evaluable and clinically meaningful - TradingViewTradingView · Fri, 31 Jul 2026 07:00:00 GMTAdcomm backs Replimune melanoma drug, despite data concern - pharmaphorumpharmaphorum · Fri, 31 Jul 2026 07:00:00 GMT